Allo CD7 CAR WU-CART-007



Subscribe to be notified of changes or updates to this page.

10 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as WU-CART-007 (“study drug”).  WU-CART-007 uses immune cells, called T cells, that are genetically changed to identify cancer cells. In this study, T cells are collected from a healthy human donor and have been modified in a laboratory. If the genetically changed T cells recognize and attach to cancer cells, they may have the ability to kill those cancer cells.

Patients with T-cell Acute Lymphoblatic Leukemia (T-ALL) or Lymphoblastic Lymphoma (LBL), where the disease has come back (relapsed) or has not responded to treatment (refractory) may be eligible for the study.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at leibfreidb [at] or 267-242-5953.

Eligibility & Criteria

IRB #:
Official Title:
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T cells (WU-CART-007) in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)
Study Phase:
Phase I
Phase II
Eligible Age Range:
12 - 30 Years
Study Categories:

Visit Criteria

As a participant in the research you will:

  • Receive a study drug WU-CART-007
  • Avoid taking certain medications (steroids, chemotherapy agents)
  • Stay in the hospital for at least 7 days after receiving the study drug
  • Complete follow up visits
  • Have research blood samples drawn